Any dosing should only be decided by a licensed clinician and limited to approved medical indications
Side effects, weight loss progress, and personal preferences can also influence the decision
The same preclinical program reported that weight loss persisted for roughly 43 days after the last dose in animal models a durability signal that helped justify moving the compound into human Phase 1 and Phase 1b studies, the latter published in The Lancet in 2022 in a multicenter, placebo-controlled trial in people with type 2 diabetes
Since the GLP-1R is highly expressed in the upstream PSN and ZI [66], it would be interesting to determine their neurochemical phenotype and whether they are activated by peripheral GLP-1R agonists to suppress food intake
Porque son perfiles regulatorios distintos
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes mellitus (T2DM) and weight management, have emerged as a promising treatment due to their anti-inflammatory and immunomodulatory properties
